You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing

    SBC: DYNAMIC ENTROPY TECHNOLOGY, LLC            Topic: NIDDK

    Abstract Diabetic ulcers or pressure ulcers are common for patients with diabetesspinal cord injuriesetcWithout proper managementsuch wounds often lead to infections such as osteomyelitis or sepsisresulting in high mortality and morbidityIn addition to bacterial infectiondiabetic patients are also more susceptible to cutaneous fungal infectionsAdvanced wound dressings and advanced wound therapies ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing

    SBC: Bondwell Technologies Inc.            Topic: 400

    Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government